TEVA - Teva Pharmaceutical Industries Limited
| Previous Close | 23.69 |
| Open | 23.59 |
| Bid | 0.00 x 4000 |
| Ask | 0.00 x 3000 |
| Day's Range | 23.38 - 23.97 |
| 52 Week Range | 11.49 - 25.96 |
| Volume | 13,578,454 |
| Avg. Volume | 12,212,698 |
| Market Cap | 23.971B |
| Beta (3Y Monthly) | 0.93 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -10.09 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | 2017-11-27 |
| 1y Target Est | 23.19 |
- CNBC•8 hours ago
Cramer's lightning round: Dropbox's stock is a buy even after the tech sell-off
Jim Cramer flags an opportunity in shares of data-focused technology play Dropbox in the lightning round.
Market Realist•15 hours agoJazz Pharmaceuticals: How Are Xyrem and Erwinaze Positioned?
Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $357.3 million in the third quarter—compared to $303.9 million in the third quarter of 2017, which reflected ~18% YoY (year-over-year) growth. Xyrem’s net revenues over the first nine months of 2018 amounted to $1.0 billion—compared to $874.2 million in the same period in 2017, which reflects 18% YoY growth.
- Insider Monkey•yesterday
4 Stocks Warren Buffett and Insiders Are Piling On
Warren Buffett is arguably the greatest investor of all time. Over his career, Buffett’s investing prowess formed one of the greatest conglomerates of all time and generated a lot of value for investors. In this article, examine four stocks that Buffett’s Berkshire Hathaway held in the second quarter and that company insiders have also bought in the last […]
- InvestorPlace•6 days ago
Even Following the Latest Surge, Mylan Stock Has Plenty of Room to Grow
Whenever a stock shoots higher, value investors justifiably hesitate on trading it. The stock priced in the good news already, leaving few extra gains ahead. So when Mylan N.V. (NASDAQ: MYL) rose by over 15% on the week, the best thing investors may do before buying Mylan stock is to look at the quarterly earnings result in detail.
- Zacks•7 days ago
Amgen (AMGN) Counts on New Drugs Amid Rising Biosimilar Woes
Amgen's newer drugs, Prolia, Xgeva, Kyprolis, are driving sales. Lower sales of mature drugs like Enbrel and biosimilar competition for Neulasta/Epogen are concerns.
- Zacks•7 days ago
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year?
Is (TEVA) Outperforming Other Medical Stocks This Year?
- Motley Fool•7 days ago
These 3 Value Stocks Are Absurdly Cheap Right Now
You can profit big from the market's mistakes.
- InvestorPlace•7 days ago
9 High-Risk Stocks to Buy for Massive Rewards
Teva Pharmaceutical (NYSE:TEVA) is doing a lot better this year — up just shy of 20%. Its key drug, Copaxone, which treats multiple sclerosis, is facing generic competition from Mylan (NASDAQ:MYL), among others. The company has sold assets to clean up its balance sheet, which has de-risked the story somewhat.
Market Realist•8 days agoHow Teva Pharmaceutical’s Products Performed Internationally
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~18% YoY (year-over-year) to $726.0 million from $882.0 million. It fell YoY to $2.3 billion in the first nine months of this year from $2.5 billion. The company’s international gross profit fell YoY to $301.0 million in the third quarter from $351.0 million, and to $942.0 million in the first nine months of this year from $1.0 billion.
Market Realist•8 days agoTeva Pharmaceutical’s Performance in European Markets
In the third quarter, Teva Pharmaceutical’s (TEVA) European revenue fell ~12% YoY (year-over-year) to $1.2 billion from $1.38 billion. Its net European revenue fell YoY to $3.98 billion in the first nine months of this year from $4.02 billion.
Market Realist•8 days agoHow Teva’s Products Performed in North American Markets
In the third quarter, Teva Pharmaceutical’s (TEVA) North American Generic Medicines revenue fell ~25% YoY (year-over-year) to $922.0 million from $1.2 billion. In the first nine months of this year, it fell ~26% YoY to $3.0 billion from $4.0 billion.
Market Realist•8 days agoA Look at Teva Pharmaceutical’s Third-Quarter Earnings
Teva Pharmaceutical’s (TEVA) GAAP net income fell YoY (year-over-year) to -$273 million from $530.0 million in the third quarter, but rose YoY to $541.0 million from -$4.9 billion in the first nine months of this year. Teva’s GAAP diluted EPS fell YoY to -$0.27 from $0.52 in the third quarter, and to $0.53 from $4.85 in the first nine months of this year. The company’s non-GAAP net income and non-GAAP diluted EPS fell YoY to $694.0 million and $0.68, respectively, from $1.0 billion and $1 in the third quarter.
Market Realist•8 days agoTeva Pharmaceutical’s Performance in the Third Quarter
In the third quarter, Teva Pharmaceutical’s (TEVA) revenue fell ~19% YoY (year-over-year) to $4.5 billion. In the first nine months of this year, Teva’s net revenue fell ~16% YoY to $14.3 billion from $17.0 billion.
- Barrons.com•8 days ago
These Health-Care Standouts Have More Room to Rise, Morgan Stanley Says
Both Bausch Health Cos. and Teva Pharmaceuticals have outperformed their peers and the market this year, but Morgan Stanley sees more gains ahead.
Market Realist•9 days agoHow Wall Street Analysts View Teva Pharmaceutical
In October, the FDA’s Oncologic Drugs Advisory Committee unanimously voted to recommend approving Teva Pharmaceutical’s (TEVA) and Celltrion’s Biologics License Application for CT-P10, a proposed biosimilar to Roche’s (RHHBY) Rituxan. The recommended approval of CT-P10 was for three indications: as a monotherapy for relapsed or refractory B-cell non-Hodgkin’s lymphoma as a first-line treatment for B-cell NHL in combination with chemotherapy as a second-line monotherapy for non-progressing B-cell NHL after cyclophosphamide-, vincristine-, or prednisone-based chemotherapy
- Benzinga•9 days ago
Teva To Deliver Cost Cuts, Earnings Surprise In Coming Years, Morgan Stanley Says In Upgrade
Teva Pharmaceutical Industries Ltd ADR (NYSE: TEVA ) last week reported a 19-percent drop in Q3 revenues, stung by generic competition to its multiple sclerosis drug Copaxone, price erosion at its U.S. ...
- ACCESSWIRE•9 days ago
Monday's Top Healthcare Stocks To Watch Ahead Of Elections
Healthcare has become the latest market to take full advantage of this trend. According to a paper by PwC called The Digital Healthcare Leap, the new trends are ripe for digital healthcare solutions in developed and emerging markets. As a result, the industry has expanded its focus to non-critical health care services to cater to this changing demand of present-day consumers.
- Zacks•12 days ago
Teva (TEVA) Q3 Earnings Beat, 2018 EPS View Up, Shares Rise
Teva's (TEVA) shares up 15% despite mixed third-quarter results as it increases its earnings and free cash flow guidance for the full year.
- ACCESSWIRE•12 days ago
Today’s Research Reports on Stocks to Watch: Teva Pharmaceutical and SELLAS Life Sciences
NEW YORK, NY / ACCESSWIRE / November 2, 2018 / Teva shares were skyrocketing on a third quarter financial report that beat analysts’ estimates and a raised outlook. Shares of Sellas Life Sciences were ...
- The Wall Street Journal•12 days ago
[$$] Teva Passes Its Check-Up
The generic drug giant reported third-quarter sales of $4.5 billion and adjusted earnings of 68 cents a share. While both figures were down significantly from a year earlier, the earnings figure topped expectations thanks to deeper cost cuts than analysts had anticipated. Teva also increased its full-year guidance for profit and free cash flow.
- Motley Fool•12 days ago
Why Teva Pharmaceutical Industries Ltd. Stock Crushed It Today
Teva's comeback continues to take shape.
- Motley Fool•12 days ago
Why Las Vegas Sands, DowDuPont, and Teva Pharmaceutical Industries Jumped Today
Find out which of these stocks climbed on strong earnings.
Associated Press•12 days agoIsrael's Teva gives upbeat outlook as restructuring proceeds
JERUSALEM (AP) — Israeli drug maker Teva Pharmaceutical Industries on Thursday reported a third-quarter loss as it proceeds with an aggressive cost-cutting program and adjusts to declines in key product categories.
- GuruFocus.com•12 days ago
Financial Results Spur 2 Stocks Higher on Thursday
Shares of Teva Pharmaceutical Industries Ltd. (TEVA) rose more than 11% on Thursday after posting third-quarter results. The company beat earnings estimates by 13 cents, but fell $20 million short of revenue expectations. The GAAP gross profit was $2.02 billion, a 24% decrease from the prior-year quarter .
